Wall Mounted Segment to Hold North America Medical Gas Outlet Market Share During 2023–2031

According to our latest study on " Europe Contract Research Organization Market Forecast to 2031 – Regional Analysis – Service Type, Product Type, Type, Application, End User, and Country," the market is expected to reach US$ 40,023.68 million by 2031 from US$ 22,885.00 million in 2024; it is estimated to register the CAGR of 8.3% during 2024–2031. The market report emphasizes the key factors driving the market and developments by prominent players. Increased outsourcing of R&D and rising demand for clinical trials bolsters the Europe contract research organization market.

Europe contract research organization market is segmented into the Germany, UK, Spain, France, Italy, Netherlands, Greece, and Rest of Europe. The UK is expected to be among the largest contributors to the contract research organization market in Europe. The contract research organization (CRO) market in the UK is likely to register significant growth in the coming years owing to the surge in clinical trials and a rise in demand for outsourced drug discovery services. According to the Association of the British Pharmaceutical Industry (ABPI), the total number of clinical trials increased by 4.3% per year, from 394 trials in 2021 to 411 in 2022. Further, the UK government encourages clinical trials by funding. For instance, in August 2024, Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme was launche by the government of UK. The government announced that NHS patients will benefit from earlier access to new treatments as the UK government launches a US$ 445.35 million (£400 million) public-private investment program. This initiative aims to enhance clinical trials, improve medicine manufacturing, and establish 18 new clinical trial hubs across the UK to accelerate research.

CROs in the UK are essential to the global biotechnology and pharmaceutical industries, providing a wide range of services, including data analysis, clinical trial management, regulatory affairs, and medical writing. These groups play a crucial role in improving drug development procedures by offering crucial assistance to academic institutions, biotechnology corporations, and pharmaceutical companies. For instance, Richmond Pharmacology, a CRO with headquarters in the UK, focuses on early-phase clinical trials. Richmond Pharmacology has completed more than 300 studies since 2001, working with global pharmaceutical and biotech companies on a wide range of medical disorders. Simbec-Orion is another prominent player that provides a comprehensive range of services, including clinical trial management, clinical pharmacology, and central laboratory support. They particularly focus on complex therapeutic areas such as oncology and rare diseases, delivering tailored solutions to address the challenges present in these fields.

The UK’s CRO sector has seen substantial growth, driven by an increasing trend among pharmaceutical and biotech companies to outsource various aspects of drug discovery and development. This expansion has led to noteworthy mergers, acquisitions, and investment activities as companies seek to enhance their service offerings and maintain competitiveness. For example, Eurofins Discovery, also a UK-based CRO, acquired DiscoveryBioMed in June 2022. The acquisition of DiscoveryBioMed enhances Eurofins Discovery’s strategy to offer the most comprehensive and highest-quality portfolio of drug discovery services and products to strengthen their capacity for supporting translational biology in drug discovery research and development..

Germany offers an ideal environment for the development and production of research-intensive, high-quality products. According to Germany Trade & Invest, in 2021, the pharmaceutical industry in Germany invested more than EUR 8.7 billion (US$ 9.85 billion) in research and development (R&D) activities. CROs in Germany provide essential services across the drug development lifecycle, including drug discovery, research, and post-approval support. By outsourcing to CROs, pharmaceutical companies can tap into specialized resources and expertise without straining their R&D budgets, contributing to the growth of the contract research organization (CRO) market.

The complexity of clinical trials is increasing over time due to regulatory compliance, which requires specialized knowledge about drugs and treatments, as well as efficient patient recruitment. CROs possess the expertise needed in this field, making it advantageous for companies to collaborate with them. As a result, the growing number of clinical trials and the evolving regulatory environment in Germany are driving the demand for the CRO market.

CROs are focusing on expanding their geographical presence in the country by adopting inorganic strategies such as partnerships and acquisitions. In October 2023, Labquality Corporation acquired P.R.I.S.M.A.-CRO GmbH, a company in Germany specializing in clinical trial services for the pharmaceutical and biotech industries. Labquality’s acquisition of P.R.I.S.M.A. strengthens its clinical trial offerings and aligns with its strategy to develop a full-service CRO. This move is expected to help Labquality expand its business in the German and Central European pharmaceutical markets.

In France he number of clinical trials to introduce new products by pharma and biotech companies is growing with technological advancements such as AI technologies. CROs in France are increasingly adopting advanced technologies to improve the efficiency and quality of clinical trials. For instance, ICTA, a full-service international CRO, uses an integrated IT platform called I-SIT to manage clinical trials, ensuring secure and efficient data handling throughout the study process.

The changing regulatory environment for clinical trials in France is also positively influencing the market. In August 2024, France introduced the Convention Unique, which includes updated templates for clinical trial agreements. These changes aim to standardize and simplify the initiation of clinical trials by providing standardized clauses for equipment and biological resources. While intended to streamline processes, these updates may also impact the overall budget due to changes in the cost of research. CROs in France play a crucial role in the pharmaceutical and biotechnology sectors by providing a wide range of services to support clinical trials and research initiatives. The surging number of clinical trials and supportive regulatory environment in the country are significantly creating the demand for CRO services.

Market players are adopting inorganic growth strategies for the development of the CRO services market in France. For instance, in September 2023, 1MED, a specialist CRO providing regulatory and clinical support to medical device companies, acquired Evamed, a CRO based in northwest France, also focused on the medical device market. This acquisition established 1MED’s presence in France and strengthened the company’s capabilities in high-complexity interventional trials with higher-risk devices.

Therefore, the Mexico medical gas outlets market is being driven by the rise in demand for elective surgeries, an increase in chronic illness management, and a surge in medical tourism. Investments in public-private partnerships and private healthcare are expected to fuel the market growth in the near future.

Italy provides clinical trial sponsors with several prestigious clinical centers to conduct commercial and academic studies across multiple therapeutic areas.

In April 2022, the European Investment Bank (EIB) announced US$ 15 million in funding to IRBM SpAIRBM, a world-leading, Italy-based CRO specializing in research and development for new biomedical and pharmaceutical solutions to combat infectious, oncologic, rare, and neurological diseases. The project includes clinical trial costs, setting up commercialization (such as market access), pre-clinical research and development costs, and working capital. Increased funding for conducting clinical trials and the discovery of new drugs for multiple therapy areas boost the contract research organization (CRO) market in the country.

By Product type, the market is segmented into cell and gene therapy, biosimilars, antibody drug conjugates, and others. The Biosimilars segment held the largest share of the Europe contract research organization market in 2024.

In terms of type, the Europe contract research organization market is bifurcated into in-house and outsource. The outsource segment held a larger share of the Europe contract research organization market in 2024.  

Based on application, the market is segmented into oncology, neurology, cardiology, infectious diseases, metabolic disorders, nephrology, respiratory, dermatology, ophthalmology, hematology, and others. The oncology segment held the largest share of the Europe contract research organization market in 2024.

By end user, the Europe contract research organization market is divided into pharmaceutical and biotech companies, medical device companies, and academic and research institutes. The pharmaceutical and biotech companies segment held the largest share of the Europe contract research organization market in 2024.   .

Smerud Medical Research Group, AURIGON GMBH, Pharmaxi LLC, Clinmark sp. z o.o, Siron Clinical, Julius Clinical, O4 Research Ltd, Medpace Holdings Inc, ProPharma Group, Precision Medicine Group, LLC, Thermo Fisher Scientific (PPD Inc), Parexel International Corp. are a few key companies profiled in the Europe Contract Research Organization market report. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com